| |
Number of cases |
Clinical presentation |
Treatment |
MLS (days) |
Need of MV |
Outcome |
| CMV |
9 |
55% symptomatic (mainly hepatosplenomegaly) |
Ganciclovir in 55.5% |
20 |
In 22.2% (CMV pneumonia) |
Favorable, 2 pulmonary disease |
| RSV |
22 |
Bronchiolitis in 77.3%, pneumonia in 22.7% |
Bronchodilator therapy in 81.8% |
14 |
In 45.5% |
Generally favorable, 4.5% (n=1) mortality |
| Metapneumovirus |
12 |
Bronchiolitis in 50%, others asymptomatic |
Bronchodilator therapy in 50% |
52 |
In 83.3% |
Favorable |
| Parainfluenza |
2 |
All bronchiolitis |
Bronchodilator therapy |
68 |
No |
Favorable |
| H1N1 |
12 |
83.3% asymptomatic, others bronchiolitis, outbreak 2009 |
Oseltamivir |
30 |
In 50% |
Favorable |
| Rotavirus |
4 |
Nosocomial, diarrhea and abdominal distention |
Not specific |
42 |
In 50% |
Favorable |
| Adenovirus |
3 |
Gastrointestinal and respiratory symptoms |
Not specific |
60 |
All |
33.3% (n=1) mortality |
| Enterovirus |
2 |
Sepsis like disease, outbreak 2007 |
Broad spectrum antibiotics |
18 |
All |
100% (n=2) mortality |
| Herpes Simplex |
1 |
Seizure |
Acyclovir |
30 |
No |
Favorable |
| Varicella Zoster virus |
1 |
Varicella |
Specific immunoglobulin and acyclovir |
7 |
No |
Favorable |